Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Psoriasis Biosimilars Market Size And Revenue Outlook Through 2030
The psoriasis biosimilars market size has observed rapid expansion in recent years. This market is expected to expand from $8.16 billion in 2025 to $9.08 billion in 2026, registering a compound annual growth rate (CAGR) of 11.3%. The market’s past growth can be attributed to the elevated cost of reference biologics, restricted patient access to treatment, the increasing occurrence of moderate to severe psoriasis, heightened physician awareness and prescriptions, and the initial approvals of TNF-alpha inhibitors.
The psoriasis biosimilars market size is anticipated to expand significantly in the coming years. It is forecast to grow to $13.79 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 11.0%. This growth during the forecast period is primarily fueled by the introduction of new biosimilars for infliximab, etanercept, and adalimumab, the expansion of hospital and online pharmacy networks, increased healthcare spending on dermatology, the rising adoption of patient assistance programs, and an increase in clinical trials for novel biosimilars. Prominent trends for this period encompass the growing acceptance of cost-effective psoriasis biosimilars, an enhanced focus on patient access and affordability, the development of subcutaneous and intravenous administration routes, the enlargement of hospital and retail pharmacy distribution channels, and the innovation of targeted therapies for various types of psoriasis.
Get A Free Sample Report With In-Depth Market Insights:
Psoriasis Biosimilars Market Industry Drivers: What’s Behind The Revenue Growth?
The increasing diagnosis rates of psoriatic arthritis are anticipated to boost the expansion of the psoriasis biosimilars market going forward. Psoriatic arthritis is defined as a chronic autoimmune disorder that causes inflammation in both joints and skin, frequently observed in individuals with a history of psoriasis. The rates of psoriatic arthritis diagnosis are on the rise, primarily because enhanced screening protocols among individuals with psoriasis enable earlier and more accurate detection by identifying subtle joint symptoms that might have previously gone unnoticed. Psoriasis biosimilars aid in managing psoriatic arthritis by offering cost-effective alternatives to biologic therapies, thereby effectively reducing joint inflammation and skin manifestations. For example, in August 2025, the National Psoriasis Foundation (NPF), a US-based non-profit patient advocacy organization, stated that approximately 1 in 3 individuals living with psoriasis are affected by psoriatic arthritis, and as many as 2.4 million Americans live with this condition. Additionally, more than 15% of people with psoriasis may also have undiagnosed psoriatic arthritis, highlighting both growing recognition and persistent underdiagnosis of the condition. Consequently, the escalating rates of psoriatic arthritis diagnoses are driving the growth of the psoriasis biosimilars market.
Psoriasis Biosimilars Market Segment Breakdown: Which Categories Lead On Revenue?
The psoriasis biosimilars market covered in this report is segmented –
1) By Drug Class: TNF-Alpha Inhibitors, Infliximab, Etanercept, Adalimumab, Other Biosimilars
2) By Disease Type: Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis
3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Topical
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By TNF-Alpha Inhibitors: Monoclonal Antibody Biosimilars, Fusion Protein Biosimilars
2) By Infliximab: Remicade Biosimilars, CT-P13 Biosimilars
3) By Etanercept: Enbrel Biosimilars, SB4 Biosimilars
4) By Adalimumab: Humira Biosimilars, ABP 501 Biosimilars
5) By Other Biosimilars: Ustekinumab Biosimilars, Secukinumab Biosimilars
#Psoriasis Biosimilars Market Growth Trends: What’s Shaping The Future Outlook?
Leading firms in the psoriasis biosimilars sector are prioritizing the development of novel solutions, including biosimilars specifically for plaque psoriasis, aiming to boost treatment availability, decrease medical expenses, and better patient results. These plaque psoriasis biosimilars offer more affordable, highly comparable substitutes for established biologic medications utilized to manage this persistent autoimmune skin condition, marked by red, flaky skin areas. As an illustration, during May 2025, Sandoz Group AG, a Switzerland-based company specializing in generic drugs and biosimilars, introduced the Pyzchiva autoinjector, which represents the initial commercially accessible ustekinumab biosimilar autoinjector. Pyzchiva holds approval for addressing plaque psoriasis, psoriatic arthritis, and Crohn’s disease in adults, in addition to plaque psoriasis in pediatric patients who are six years of age or older (and weigh above 60 kg). This autoinjector was crafted to improve patient compliance and overall quality of life, incorporating features such as precise automatic dosing, diminished injection discomfort, a compact form factor, and adaptable storage choices, facilitating easier self-administration.
Psoriasis Biosimilars Market Leading Players And Competitive Positioning
Major companies operating in the psoriasis biosimilars market are Pfizer Inc., Amgen Inc., Sandoz Group AG, Fresenius Kabi AG, Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Samsung Bioepis Co. Ltd., Zydus Lifesciences Ltd., Celltrion Inc., Bio-Thera Solutions Ltd., Coherus BioSciences Inc., mAbxience S.A., Alvotech hf.
View The Full Psoriasis Biosimilars Market Report:
Psoriasis Biosimilars Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the psoriasis biosimilars market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psoriasis biosimilars market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
